INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediaAlpha, Inc. – MAX

Pomerantz LLP is investigating claims on behalf of investors of MediaAlpha, Inc. (“MediaAlpha” or the “Company”) (NYSE: MAX).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether MediaAlpha and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for […]

MaidCentral Strategy Summit Celebrated as Transformative Event for the Residential Cleaning Industry

The MaidCentral Strategy Summit 2025, held September 17-19 at Castle Keepers House Cleaning in North Charleston, united residential cleaning business leaders for three days of masterclasses, keynote sessions, and data-driven success stories. Attendees hailed the Summit as the most impactful event in the residential cleaning industry, setting a new benchmark for professional development, innovation, and

FFIV Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages F5, Inc. (NASDAQ: FFIV) Investors with Significant Losses to Contact the Firm

FFIV Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages F5, Inc. (NASDAQ: FFIV) Investors with Significant Losses to Contact the Firm GlobeNewswire October 23, 2025 RADNOR, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

(NASDAQ:ALXO), -Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports ALX2004 differentiation in EGFR-ADC class and continued evaluation in first-in-human trial –Initial safety data from ongoing ALX2004 Phase 1 trial anticipated in the first half of

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

(NASDAQ:ZYME), Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer 64% overall response rate in gynecological cancers at doses greater-than or equal to6.4mg/kg Responses observed at all doses evaluated at 3.2mg/kg and above demonstrating wide therapeutic

Sports.com Builds on 10 Million-View Milestone with Second Season of Hit LATAM Series Maximo Futbol

Sports.com Builds on 10 Million-View Milestone with Second Season of Hit LATAM Series Maximo Futbol SEGG Media Expands Original-Content Footprint as Sports.com Studios Greenlights Season Two GlobeNewswire October 23, 2025 FORT WORTH, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) (“SEGG Media” or the “Company”), the global sports, entertainment, and

Securities Lawsuit Alert: Tronox Holdings plc (TROX) – Contact Levi & Korsinsky Before November 3, 2025

NEW YORK, NY / ACCESS Newswire / October 23, 2025 / If you suffered a loss on your Tronox Holdings plc (NYSE:TROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/tronox-holdings-plc-lawsuit-submission-form?prid=173679&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference GlobeNewswire October 23, 2025 -Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports ALX2004 differentiation in

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⺠at AACR-NCI-EORTC Conference GlobeNewswire October 23, 2025 Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer 64% overall

Frederick Flying Cows To Host a World Record Breaking Festival This Weekend!

A World Record Attempt, Live Music, Helicopter Candy Drop, and More – the Frederick Flying Cows Bring the Ultimate Fall Festival to the Great Frederick Fairgrounds on Sunday. The wait is over – Cowfest is finally here! This Sunday, October 26, the Frederick Flying Cows invite families, fans, and festivalgoers to join them at the

Scroll to Top